These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9123421)

  • 21. Tacrolimus therapy for refractory renal allograft rejection: experience with steroid withdrawal.
    Cronin DC; Bruce DS; Newell KA; Josephson MA; Millis JM; Piper JB; Ruebe M; Kirby M; Thistlethwaite JR; Woodle ES
    Transplant Proc; 1997; 29(1-2):307. PubMed ID: 9123010
    [No Abstract]   [Full Text] [Related]  

  • 22. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center.
    Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B
    Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [OKT3 treatment of refractory renal allograft rejection].
    Xu J; Ma J; Bai X
    Zhonghua Wai Ke Za Zhi; 1997 Apr; 35(4):223-5. PubMed ID: 10374543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased risk of early rejection correlates with recovery of CD3 cell count after liver transplant in patients receiving OKT3 induction.
    Sheiner PA; Guarrera JV; Grunstein E; Emre S; Guy SR; Schwartz ME; Miller CM; Boros P
    Transplantation; 1997 Oct; 64(8):1214-6. PubMed ID: 9355846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cadaveric renal transplantation against a positive historic crossmatch under tacrolimus immunosuppression: long-term follow-up.
    Lyne JC; Vivas CA; Shapiro R; Scantlebury VP; Hakala TR; Starzl TE; Jordan ML
    Transplant Proc; 1997; 29(1-2):312. PubMed ID: 9123015
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK.
    Muduma G; Odeyemi I; Pollock RF
    J Med Econ; 2015; 18(12):1050-9. PubMed ID: 26201252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppression for recipients of kidneys from non-heart-beating donors: comparison of triple therapy and OKT3 regimens.
    Kehinde EO; Wheatley T; Feehally J; Nicholson ML; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1338-9. PubMed ID: 8658684
    [No Abstract]   [Full Text] [Related]  

  • 28. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy.
    Ciancio G; Carreno M; Mathew J; Ricordi C; Garcia R; Karatzas T; Fuller L; Cirocco R; Burke G; Webb M; Nery J; Tzakis A; Roth D; Esquenazi V; Miller J
    Transplant Proc; 1996 Apr; 28(2):943-4. PubMed ID: 8623473
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach.
    Jürgensen JS; Arns W; Hass B
    Eur J Health Econ; 2010 Feb; 11(1):15-25. PubMed ID: 19296139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection.
    Platz KP; Mueller AR; Zytowski M; Bechstein WO; Blumhardt G; Lobeck H; Neuhaus P
    Transplant Proc; 1995 Feb; 27(1):1111-3. PubMed ID: 7533357
    [No Abstract]   [Full Text] [Related]  

  • 31. [OKT3 for recipients with steroid-resistant acute rejection after liver transplantation].
    Wu LW; He XS; Zhu XF; Wang DP; Ju WQ; Tai Q; Huang JF
    Zhonghua Gan Zang Bing Za Zhi; 2007 Nov; 15(11):857-8. PubMed ID: 18073076
    [No Abstract]   [Full Text] [Related]  

  • 32. Tacrolimus rescue therapy in patients with rejection and long-term dialysis after kidney transplantation.
    Witzke O; Becker G; Erhard J; Lütkes P; Szabo A; Philipp T; Heemann U
    Clin Nephrol; 1998 Jan; 49(1):24-7. PubMed ID: 9491282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of immunosuppressive drugs: an empirical example using a secondary database of hospital charges.
    Schommer JC; Pathak DS; Grauer DW
    Transplant Proc; 1996 Apr; 28(2):906. PubMed ID: 8623455
    [No Abstract]   [Full Text] [Related]  

  • 34. OKT3 rescue therapy for 63 refractory rejections in 405 renal allografts.
    Uchida K; Namii Y; Tominaga Y; Haba T; Tanaka H; Ichimori T; Uemura O; Morozumi K; Hayashi S; Yokoyama J; Takagi H
    Transplant Proc; 1996 Jun; 28(3):1358-9. PubMed ID: 8658693
    [No Abstract]   [Full Text] [Related]  

  • 35. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group.
    Peeters P; Kazek M; Abella I; Noble I
    Transplant Proc; 1998 Aug; 30(5):1838-42. PubMed ID: 9723301
    [No Abstract]   [Full Text] [Related]  

  • 36. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.
    Kliem V; Radermacher J; Hiss M; Pethig M; Burg M; Brunkhorst R
    Transplant Proc; 1999 Nov; 31(7A):37S-40S. PubMed ID: 10576041
    [No Abstract]   [Full Text] [Related]  

  • 37. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.
    McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P
    J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacoeconomic study of tacrolimus-based versus cyclosporine-based immunosuppressive therapy following liver transplantation.
    Rabkin JM; Corless CL; Rosen HR; Olyaei AJ
    Transplant Proc; 2001; 33(1-2):1532-4. PubMed ID: 11267411
    [No Abstract]   [Full Text] [Related]  

  • 39. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
    Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
    Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.